Skip to main content
NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%
BP

BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ • Healthcare

$8.81
-$0.25 (-2.9%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$9.07
Previous Close$8.81
Day Range$8.8 - $9.23
Avg. Volume (3M)3.1M
Market Cap$2.2B
52 Week Range
$6$11.22
Next EarningsIn 53 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$218.2M100%
Gross Profitminus cost of goods$214.4M98%
Operating Incomeminus R&D and overhead$98.4M45%
Net Incomeminus taxes and the rest$78.3M36%

In plain terms: out of every $100 in revenue, BioCryst Pharmaceuticals, Inc. keeps $36 as net profit.

Fundamentals & Financials

Revenue (TTM)
$940.6M
Net Income (TTM)
-$384.6M
EPS (TTM)
-$1.44
ROA (TTM)
-68.96%
Current Ratio
2.32

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+1500.0%Q1 2026$1.12
-5066.7%Q2 2026-$2.98
+94.6%Q3 2026$0.3
Next

Nov 2

in 53 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +94.6%

BioCryst Pharmaceuticals’ revenue topped consensus in the second fiscal quarter of 2026, with results reported August 5, 2026, as revenue rose 33.6% to about $218.2 million, up from $163.4 million a year ago. On the consensus yardstick, revenue of $218.2 million topped the $183.3 million estimate (+19.1%), pointing to a materially higher quarter than analysts were modeling. Profitability was high on a margin basis, with gross margin at roughly 98% and operating margin around 45%, alongside operating income of about $98.5 million; gross profit came in at roughly $214.4 million. The company also generated operating cash flow of about $104.3 million during the quarter. For the next period, consensus calls for EPS of $0.10 on revenue of $165.4 million.

View full earnings history

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. develops and commercializes biotechnology medicines for rare and infectious diseases, with $874.8 million in revenue in FY2025. The NASDAQ-listed BCRX company centers on small-molecule therapeutics, particularly orally administered drug candidates, and sells approved products for hereditary angioedema and influenza.

Name
BioCryst Pharmaceuticals, Inc.
CEO
Charles K. Gayer
Website
www.biocryst.com
Industry
Healthcare
Year Founded
1986
Employees
435

Today's Snapshot

AI-generated

BCRX ended yesterday 2.9% down at 8.81.

Trading Volume

Above 10d avg 3.5M

5.1M

vs S&P 500 Today

Underperforming Market

-2.39%

Updated: September 10, 2026 at 12:12 UTC

Technical Indicators

1 Buy2 Neutral5 Sell
BCRX shows a bearish short-to-medium picture as the stock sits below most short and medium moving averages while trading just above the 200-day averages, a split that favors near-term sellers. Momentum measures reinforce the downside, with RSI in the mid-30s and a deeply negative CCI, while MACD sits slightly negative, signaling declining price impetus. Volume-based pressure is evident from a large negative on‑balance volume, and the low ADX indicates the downtrend lacks strong conviction. ATR is modest, suggesting contained volatility. Technical takeaway: Sell — near-term momentum and volume favor sellers despite a slightly higher 200-day level.
All signals
  • EMA (5 indicators)$8.68 - $9.67
    Sell
  • RSI (14)36.44
    Neutral
  • Stochastic %K (14, 3, 3)24.77
    Neutral
  • MACD Level (12, 26)-0.05
    Sell

Peers & Related Assets

SYRESpyre Therapeutics, Inc.
$86.93-4.3%
TRVITrevi Therapeutics, Inc.
$16.64-1.1%
ZYMEZymeworks Inc.
$27.15-3.4%
STOKStoke Therapeutics, Inc.
$29.92-0.4%
NTLAIntellia Therapeutics, Inc.
$12.21-4.2%
MAZEMaze Therapeutics, Inc.
$24.58-6.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.